Precision Prescribing in the ICU: Evaluating BioFire® FilmArray® Pneumonia Panel and Standard Culture-Guided Therapy...

Ventilator-associated pneumonia (VAP) is a leading cause of morbidity and mortality in ICUs. Timely identification of pathogens is critical to initiating targeted antimicrobial therapy. This study evaluated the clinical and diagnostic impact of the BioFire® FilmArray® Pneumonia Panel (BFPP; BioFire Diagnostics, LLC, Salt Lake City, UT, USA), a rapid multiplex PCR-based test, compared to conventional culture and sensitivity testing in patients with VAP.

A prospective observational longitudinal study was conducted in a North Indian tertiary care medical college. A total of 106 patients with VAP, diagnosed based on the National Healthcare Safety Network (NHSN) infection-related ventilator-associated complication (IVAC) criteria, were equally divided into two groups. Group A underwent both BFPP and culture testing; Group B was assessed using culture-based diagnostics alone. Demographic data, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, ICU stay, ventilation duration, extubation timing, antibiotic usage, and 28-day mortality were recorded and analyzed.

The mean APACHE II score was higher in the culture group (30.7 ± 6.2) than in the BFPP group (29.5 ± 7.1; p = 0.20), but was not statistically significant. ICU stay was significantly shorter in BFPP-positive patients (median nine days) than in culture-positive patients (median 13 days; p = 0.021). Early extubation within seven days was more frequent in the BFPP group (73.7%) compared to the culture group (52.9%; p = 0.047). While overall 28-day mortality was lower in the BFPP group (55.8%) compared to the culture group (62.3%), the difference was not statistically significant (p = 0.21). However, sex-stratified analysis showed significantly lower mortality among both males (p = 0.037) and females (p = 0.048) in the BFPP group. A concerning finding was the higher mortality rate in BFPP-negative patients (43.5%) compared to culture-negative cases (38.5%; p = 0.042).

The integration of the BFPP into the diagnostic workflow for VAP demonstrated improved intermediate clinical outcomes, including reduced ICU stay, earlier extubation, and shortened ventilation duration. While overall mortality benefits were not statistically significant, subgroup analyses indicated a potential survival advantage with BFPP-guided management, particularly in pathogen-positive cases. However, caution is warranted in interpreting negative molecular results without clinical correlation, as these may lead to delayed or inappropriate therapy. This study supports the adoption of molecular diagnostics as a complementary tool to conventional cultures in managing VAP, especially when paired with robust clinical judgment and antimicrobial stewardship.